| abstract |
A compound having the structure ** Formula ** where R1 is selected from the group consisting of H, F, C3-C6 cycloalkyl and C1-C4 alkyl, R2 to R11 is selected from the group consisting of H, C1-C3 alkyl , C3-C6 cycloalkyl, fluorine, hydroxy and C1-C6 alkoxy, and pharmaceutically acceptable acid addition salts of Compound (I), racemic mixtures of Compound (I), or the corresponding enantiomer and / or optical isomer of Compound (I ), and the polymorphic forms of Compound (I), as well as the tautomeric forms of Compound (I). |